Longevity & AgingKorean Pharma Giant Acquires Age-Reversal Cell Reprogramming Platform
Daewoong Pharmaceutical, a South Korean drug company, has acquired the core technology from Turn Biotechnologies, a US firm pioneering partial cellular reprogramming. The ERA platform uses mRNA to deliver reprogramming factors that restore youthful cellular function without fully reverting cells to a stem-cell state, which would carry cancer risk. Daewoong plans to apply the technology initially to eye and ear diseases — conditions common in aging populations where localized drug delivery is feasible. The deal signals that partial reprogramming, long regarded as scientifically exciting but commercially speculative, is maturing into serious pharmaceutical infrastructure. South Korea's aging demographics give the company strong incentive to lead in this space.
